AstraZeneca Targets Korean Co. Over Nexium Patents
AstraZeneca filed a complaint Wednesday in the U.S. District Court for the District of New Jersey, alleging that Hanmi and three affiliates violated the patents by submitting an abbreviated new drug application for 20 and 40 milligram esomeprazole strontium capsules to the U.S. Food and Drug Administration.
The suit is one of many AstraZeneca has launched...
Already a subscriber? Click here to login